A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Pathological diagnosis of complex SCLC or transformed SCLC.
• •Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3.
• •Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
• •Has severe, uncontrolled or active cardiovascular disorders.
• •Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
• •Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).
• •Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases.
• •Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids.
• •Has documented Hepatitis B or Hepatitis C